AEterna Zentaris Inc. (AEZS)

NASDAQ: AEZS · Delayed Price · USD
0.340
-0.020 (-5.48%)
At close: Jan 18, 2022 4:00 PM
0.355
0.015 (4.412%)
Pre-market:Jan 19, 2022 4:15 AM EST
Market Cap42.65M
Revenue (ttm)3.65M
Net Income (ttm)-5.12M
Shares Out125.45M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,426,635
Open0.355
Previous Close0.360
Day's Range0.334 - 0.360
52-Week Range0.335 - 3.620
Beta2.00
AnalystsBuy
Price Target2.00 (+488.2%)
Earnings DateNov 4, 2021

About AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maxi...

IndustryBiotechnology
IPO DateJul 18, 1996
CEOKlaus Paulini
Employees12
Stock ExchangeNASDAQ
Ticker SymbolAEZS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for AEZS stock is "Buy" and the 12-month stock price forecast is 2.00.

Price Target
$2.00
(488.24% upside)
Analyst Consensus: Buy

News

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

1 week ago - GlobeNewsWire

Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors

3 weeks ago - GlobeNewsWire

3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today

A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Toda...

Other symbols:ZOMPROG
3 months ago - InvestorPlace

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified ...

4 months ago - GlobeNewsWire

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

5 months ago - GlobeNewsWire

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other symbols:AMRNDRRXGLBSLOTZMDWD
6 months ago - PennyStocks

Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders

7 months ago - GlobeNewsWire

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

7 months ago - GlobeNewsWire

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a P...

- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for the ...

8 months ago - GlobeNewsWire

Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis

Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational new drug...

8 months ago - Benzinga

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")

8 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the Q2 Virtual Investor Summit

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET

8 months ago - GlobeNewsWire

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment...

In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development...

8 months ago - GlobeNewsWire

Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a d...

8 months ago - GlobeNewsWire

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets

8 months ago - GlobeNewsWire

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientif...

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology

8 months ago - GlobeNewsWire

Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

8 months ago - GlobeNewsWire

3 Penny Stocks to Watch During the Last Week of April

As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:MICTZSAN
8 months ago - PennyStocks

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

– Company executing on growth strategy to build-out pipeline of development assets

9 months ago - GlobeNewsWire

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

9 months ago - GlobeNewsWire

AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today

Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting H...

10 months ago - InvestorPlace

Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vacc...

Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-1...

10 months ago - Benzinga

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerz...

- Company secures next step to continue to build-out pipeline of assets

10 months ago - GlobeNewsWire

If You Like Long Shots, Aeterna Zentaris Stock Is Worth a Gamble

AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is Wor...

10 months ago - InvestorPlace

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program fo...

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will ...

10 months ago - GlobeNewsWire